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The capacity of pluripotent stem cells both for self‑renewal and to differentiate into any cell type 
have made them a powerful tool for studying human disease. Protocols for efficient differentiation 
towards cardiomyocytes using defined, serum‑free culture medium combined with small molecules 
have been developed, but thus far, limited to larger formats. We adapted protocols for differentiating 
human pluripotent stem cells to functional human cardiomyocytes in a 96‑well microplate format. The 
resulting cardiomyocytes expressed cardiac specific markers at the transcriptional and protein levels 
and had the electrophysiological properties that confirmed the presence of functional cardiomyocytes. 
We suggest that this protocol provides an incremental improvement and one that reduces the impact 
of heterogeneity by increasing inter‑experimental replicates. We believe that this technique will 
improve the applicability of these cells for use in developmental biology and mechanistic studies of 
disease.
Human pluripotent stem cells, hPSCs, including human embryonic cells, ESCs and human induced pluripotent 
stem cells, iPSCs, are increasingly used in both drug discovery and to study disease and tissue development. An 
important feature of human pluripotent stem cells (hPSCs) is their ability to differentiate into virtually any cell 
type including  cardiomyocytes1–3. Previous studies have shown that stem cell-derived cardiomyocytes share 
characteristics and functional properties of primary human heart  tissue4–6. Monolayer directed differentiation, 
together with a combination of small molecules and well-defined culture media have enhanced the generation 
of cardiomyocytes at relative high purity (> 80%) without the need for additional growth  factors7–9. Variation in 
differentiation efficiency and low reproducibility have nevertheless remained problematical and these have been 
variously ascribed to initial seeding densities and confluency and the effect of batch variability of compounds 
used in the differentiation  process7,10–12. Furthermore, inter- and intra-clonal variation in both hESC and hiPSC 
lines, as demonstrated by differences in gene and protein expression, DNA methylation, and differentiation 
potential, have a major impact on the efficiency of  differentiation8,13–16. To overcome such problems, and provide 
an enabling platform for studying etiology of the disease in early developmental stages, we investigated cardio-
myocyte differentiation using defined media and small molecules in a 96-well plate format. Compared with larger 
plate formats, the 96-well plate format allows an increased number of replicates, giving a greater potential for 
reproducibility, while still being cost-effective.
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Optimizing cardiomyocyte differentiation in 96 well format. As differentiation yield is affected by 
the quality of hESCs/hiPSCs, the matrix, media, small molecules, cell density and cell  confluency8,12,17,18, we eval-
uated these factors in a 96-well format. We used two hESC lines (H1 and H9) and two hiPSC lines: Detroit 551-A 
and AG05836B-151,19–21. In order to account for potential differences in the reprogramming methods employed, 
we used a retroviral reprogrammed line (Detroit 551-A) and an integration free Sendai virus reprogramed line 
(AG05836B-15). Further, we changed propagation matrix and media to Geltrex and Essential 8 Medium (E8) 
respectively. Figure 1 shows the time line of differentiation, the media and small molecules used, some of the 
developmental markers studied and colony morphology.
We investigated confluency by initiating differentiation at 30–40%, 60–70% and 80–90% confluency and 
found that 60–70% confluency gave rise to a culture with the highest percentage of functional cardiomyocytes 
on day 15 (D15) of differentiation (Fig. 2). Then, we estimated the cell density needed to cover 60–70% of the 
well area within a minimum of 2 days after cell seeding. Seeding involves resolving hPSC colonies into single cell 
suspension and/or small clumps containing two to six cells using E8 medium supplemented by Y27632. Cells were 
incubated at 37 °C overnight in this combination and after 24 h the medium changed to fresh E8 medium. Thus, 
estimating seeding density required a minimum 2 days in culture to provide enough time for the cells to recover 
and reach the desired confluency. We identified a density of 2.4 × 104 cells/cm2 for both hESCs and hiPSCs as 
Figure 1.  An overview of the protocol. (A) Schematic of representation of differentiation protocol from hPSCs 
to differentiated cardiomyocytes. The different media and small molecules used at each stage are shown together 
with the markers that define the stage of differentiation. (B) Phenotypic overview of H1 culture at different 
differentiation stages. Differentiation was started when the confluency of the culture reached 60–70% (Day 0). 
The quality of the hPSC colonies was checked visually (i.e., homogeneous appearing colonies with clear borders 
and the absence of obvious differentiating zones). Cells were treated with 6 µM (hiPSCs) or 8 µM (hESCs) 
CHIR99021 (CHIR) on day 1 for 24 h followed by treatment with IWP2 for 48 h on day 3. By day 8, beating 
islands of cardiomyocytes covered most of the space in each well. Pictures were taken using inverted light 
microscopy (Leica DML 1000). Scale bars, 50 μm. The quality of the hPSC colonies was investigated with higher 





optimal for generating areas of beating cardiomyocytes by day 7 and spontaneous contractions of larger areas by 
day 9 to 10 (see Supplementary Fig. S1 and Video S1). The lines used in these experiments were 60–70% conflu-
ent within 2–3 days, however, time to optimal confluency may vary for other cell lines. Further, we also noted 
that any deviation in confluency without reciprocal concentration adjustment of the small molecule CHIR99021 
resulted in either increased cell death or low differentiation efficiency. We found that 8 μM was optimal for hESCs 
while for hiPSCs, 6 μM CHIR99021 resulted in high levels of  TNNT2+ cells on D15.
Human ESCs/hiPSCs were propagated on Geltrex under feeder free conditions in Essential 8 Medium (E8) 
at 2.4 × 104 cells/cm. Within 3 days, they reached a confluency of 60 to 70%, the ideal point to induce differen-
tiation by applying the GSK3 inhibitor CHIR99021, in concentration-cell-dependent manner. The inhibitor of 
WNT production-2, IWP2, was added 72 h post differentiation induction for 48 h. Fresh medium was provided 
Figure 2.  The impact of confluency on differentiation efficiency. The figure shows the morphology of 
Detroit551-A cell culture with different confluency prior to differentiation initiation and monitoring 
them at different stages of differentiation process. Finally estimation of TNNT2 + cells in the culture using 
flow cytometry. (A) Cells cultured to a confluency of 60–70% prior to differentiation initiation. Beating 
cardiomyocytes appeared on day 7 of differentiation and staining the cells for TNNT2 marker showed a high 
level of TNNT2 + cells on day 15. (B) This panel shows Detroit 551-A at a starting confluency of 80–90% 
on day 1 and the presence of few beating clumps on day 8 after initiation of differentiation. Flow cytometry 
revealed low level of TNNT2 + cells in the culture on day 15. (C) This panel shows morphology of Detroit 
551-A cells, cultured to a confluency of 30–40% prior to differentiation. This initial confluency gave rise to no 
cardiomyocytes. Cells started to die just after 24 h treatment with CHIR99021 (day-1) and most were dead 
after 3 days. All Pictures were taken using inverted light microscope (Leica DML 1000). Scale bars, 500 μm. 
Cardiomyocyte population were estimated using flowcytometer Sony cell sorter SH800 (Sony Biotechnology 






(RPMI/B-27 without insulin) on day 5, and from day 7 cells were fed with fresh RPMI/B-27 (with insulin) every 
two other days (Fig. 1). We observed areas of beating cardiomyocytes by day 7 and by day 9—10, spontaneous 
contractions could be seen in large areas of the well (see Supplementary Video S1). Contractile cardiomyocytes 
were collected from day 10—15 for further analysis.
Characterizing cardiomyocytes derived from human pluripotent stem cells. Assessment of de-
velopmental markers throughout differentiation. Differentiation from hPSC toward the cardiac lineage involves 
formation of a primitive-streak-like population, from which all endodermal and mesodermal lineages develop 
including cardiovascular progenies i.e. cardiomyocytes, endothelial cells and smooth muscle cells. To ensure 
that differentiation followed the correct developmental route, we monitored the expression levels of key mark-
ers at time points corresponding to stage-specific transitions including—pluripotency state (D0), germ layer 
specification (D3), progenitor state (D5) and committed cardiomyocytes (D15) in the ES line H1 (Fig. 3) and 
we confirmed this in the Detroit IPSC line (Fig. S2). As expected, treatment of hPSC with CHIR99021 resulted 
in decreased expression of pluripotency genes NANOG and POU5F1, and the appearance of early mesodermal 
markers such as MESP1, MIXL1 and T at the highest level on D3 of differentiation (Fig.  3, Supplementary 
Figs. S2 and S3A). Further differentiation of H1 and Detroit 551-A to cardiac progenitor was defined by the 
increased expression of ISL1 and TEMEM88 on D5, and to committed cardiomyocyte defined by the specific 
markers such as TBX5, TNNT2, MYH6 and MYL7 (Fig. 3, Supplementary Figs. S2 and S3A). The gene expres-
sion data revealed the gradual increase of GATA4 and ATP2A2 expression while cells were navigating from 
germ layer specification (D3) towards the committed cardiomyocytes (D15), and expression of cardiac specific 
markers TNNT2 and MYL7 coincided with maturation and contractile activity (Fig. 3, Supplementary Figs. S2 
and S3A). These studies also showed the presence of MYL2, a marker for ventricular myocytes, from day 12 
(Supplementary Fig. S3A).
To ensure that we were seeing appropriated maturation, we investigated the expression of mature cardio-
myocyte markers such as HOPX and MYH76 at a later stage of differentiation, D30. We showed that HOPX and 
MYH7 increased at D30 of differentiation and MYH6 fell (Supplementary Fig. S4).
We confirmed our gene expression findings using immunocytochemistry (Fig. 4 and Supplementary Fig. S3). 
We assessed the hPSCs for pluripotency and found expression of POU5F1 and no evidence of the cardiomyocyte 
marker TNNT2 in hPSC (day 0) prior to initiation of the differentiation. By day 7 of the differentiation process, 
we observed a marked reduction in the expression of POU5F1 and the appearance of the cardiomyocyte marker 
TNNT2 (Supplementary Fig. S3B). Next, we assessed cells committed to the cardiac lineage by evaluating the 
expression of ISL1 and NKX2-5 that define the cardiac progenitor stage. We found ISL1 and NKX2-5 positive 
cells by day 6 of the differentation (Fig. 4A) and TNNT2 was robustly detected by day 10 (Fig. 4A). Staining with 
an antibody against myosin light chain 7 (MYL7), a specific marker for atrial myocytes, revealed the presence of 
cardiac sarcomeres in the cells within D10-12 of differentiation (Fig. 4B-ii). Furthermore, we found the expression 
of connexin 43 (GJA1), a marker for the gap junctions in  TNNT2+ cells on D10-12 of differentiation (Fig. 4B-iii). 
Co-staining of MYL7 and troponin I3 (TNNI3) that is specefic to the cardiac muscle cells (Fig. 4B-iv) confirmed 
the presence of committed cardiomyocytes in the culture on D10-12 of differentiation.
Quantification of cell composition using flow cytometric analysis. The major cell types formed during cardiac 
lineage differentiation are cardiomyocytes, smooth muscle and endothelial cells (for  review22). Co-staining of 
the cells for markers of committed cardiomyocytes (TNNT2 and MYL7) at later stages of differentiation (Day12-
19) revealed that 82 ± 7% and 60 ± 10% of the cells from the H1 culture were positive for these markers whereas 
85.7 ± 3% of the Detroit551-A cells were positive for TNNT2 and 79.7 ± 3% of them were positive for MYL7 
(Fig. 5A). Based on flow cytometric results, H9 had the lowest differentiation efficiency with 47 ± 13% TNNT2-
positive and 45% MYL7- positive cells. We then stained cardiomyocytes for CDH5 (a marker for the endothelial 
lineage) and ACTA2 (smooth muscle) on day 15. This analysis confirmed the presence of smooth muscle and 
endothelial cells, which are expected to arise as a by-product during cardiac lineage differentiation (Fig. 5C).
We used flow cytometry to investigate the relative proportions of endothelial and smooth muscle cells in car-
diac cultures on  Day1523. The surface markers CD144 and CD140b were used to identify endothelial and smooth 
muscle respectively. Parallel, samples from the same 96 well plate were stained with an internal cardiomyocyte 
marker, TNNT2 to provide an estimate of the number of cardiomyocytes (Fig. 5B). In the H1-derived cardiomyo-
cyte culture 74.5 ± 8% were TNNT2 positive cells, 9.5 ± 2.94% stained for the smooth muscle marker (CD140b) 
and only 3.71 ± 0.81% of the population expressed the endothelial marker (CD144) (Fig. 5B). In the Detroit 
551-A culture, the proportion of TNNT2 positive cells was 77 ± 0.18% while 18.45 ± 0.1% were CD140b positive 
cells and 5.53 ± 0.02% were endothelial cells. In the AG05836B-15 culture 67.2 ± 0.2% were TNNT2 positive cells, 
while 21 ± 0.1% and 2 ± 0.007% of the cells were positive for CD140b and CD144 markers respectively (Fig. 5B).
Investigating the inter-well heterogeneity. In order to investigate the heterogeneity between wells, we extracted 
RNA from multiple wells and performed qPCR to assess the expression of TNNT2 and NKX2-5 relative to a 
housekeeping gene GAPDH. We selected up to twelve wells of a differentiation run at random and isolated total 
RNA using the MagMAx isolation kit. We looked at 2 differentiation runs of H1 and from the first analysed 12 
wells of one plate while on the second run we analysed multiple wells of 3 different plates. We also isolated total 
RNA of multiple wells from 3 different plates of one run of Detroit 551-A differentiation. The data is shown in 
supplementary table S1online. The variation is shown in Fig. 6 and we calculated the coefficient of variation 
between these CT values, which varied between 1.96 and 7.30% confirming that there were similar numbers of 





Figure 3.  Characterization of H1-derived cardiomyocytes by gene expression. Relative quantification of mRNA 
expression profiles of 18 markers, representing the different stages of differentiation from hPSC to the cardiac 
lineage. Data are collected from the differentiation of hESC-H1 toward cardiomyocytes and presented as the 
mean of three independent differentiation runs and error bars are the standard deviation of the mean. Changes 





Electrophysiological validation of hiPSC‑derived cardiomyocyte. Cardiac function including 
rhythmicity and contractility depend on the expression of number of ion channels such as sodium, potassium 
and calcium channels. To test whether the differentiated cardiomyocytes had proper electrophysiological prop-
erties, we employed Microelectrode arrays, MEA, and challenge them with different cardiac drugs. Microelec-
trode arrays provide a highly sensitive, non-invasive method for studying physiological properties of electri-
cally active cells. MEA records electrical waveform signals that are called extracellular field potentials (FPs) and 
which are generated and shaped by monolayers or small clusters of cardiomyocytes. FP contour represents the 
cardiac action potential and, reflects to some extent the electrocardiogram recording. Typically, one sees a rapid 
upstroke that corresponds to the  Na+ influx (R/Q peak) and membrane depolarization, a slow wave/plateau 
phase thought to correspond to the  Ca2+ influx, and a repolarization phase corresponding to a predominant  K+ 
efflux (T peak) (Fig. 7A).
We transferred H1 and Detroit551-A line-derived cardiomyocytes into the MEA chamber on day 11–13 
of differentiation and monitored the steadiness and beat consistency signatures up to 14 days (Day 12–26 of 
differentiation). The period of observation was selected based on the previous studies suggesting the best stage 
of differentiation for transferring the cardiomyocytes to MEA chamber for checking their electrophysiological 
 activities5,24.
H1-derived cardiomyocytes showed an average FP duration of 298 ± 20 ms, and a beat interval (BI) of 42 ± 2 
beats/min, whereas Detroit551-A-derived cardiomyocytes showed an average FP duration of 75 ± 5 ms, and 
a BI of 49 ± 4 beats/min, respectively. Beating interval became more irregular after 26 days in culture as has 
been previously  described5. To test functionality of the hPSC-derived cardiomyocytes, the following drugs were 
applied—β1 and β2 adrenoreceptor agonist isoproterenol (1 µM), potassium channel antagonist E4031 (1 µM), 
sodium channel antagonist tetrodotoxin (TTX, 5 µM)), L-type calcium channel antagonist nifedipine (5 nM), and 
the 5-hydroxytryptamine (serotonin) receptor -HT4 agonist and HT3 antagonist Mosapride (350 nM) (Fig. 7Bi-
v, Table 1). While a more limited number of drugs were applied to Detroit 551-A, these cells exhibited the same 
alterations in their electrophysiological pattern following the application of isoproterenol and E4031.
As expected, isoproterenol increased the beating frequency and led to a significant reduction of the FP 
duration (FPD, Fig. 7Bi, Table 1). E4031 reduced the FP amplitude (FPA, Fig. 7Bii, Table 1) as expected, but 
contrary to other reports, we observed an increased in the FP duration (FPD) and a minor prolongation of the 
beat  interval5,24. Application of TTX led to significant reduction of the positive peak amplitude (pPA), increased 
FPA, prolonged BI, but no effect on FPD (Fig. 7Biii, Table 1). Nifedipine, behaved as described by reducing the 
pPA and FPD with no effect on the BI (Fig. 7Biv, Table 1).  Mosapride25,26 impacted the FPA and led to a notable 
Figure 4.  Cardiomyocyte characterization. Cardiomyocyte culture consists of several layers of cells, which 
makes it difficult to stain the cells in single well of 96 well plate. Cardiomyocyte characterization using 
immunocytochemistry was performed by transferring cells one well of 96 well plate into a single well of 12 well 
plate. (A) Detroit 551-A cells were differentiated in a 96 well format and transferred at day 5–12-well plates 
and cultured for a further 1–5 days. They were then stained for markers of cardiomyocyte differentiation (i.e. 
differentiation time points 6 and 10 days). Scale bar, 100 µm. (B) hiPSCs differentiated to CM and transferred 
on day 8 from 96-well plate to cover slips in a 12-well plate. (i) Detroit 551-A stained with TNNT2; (ii) 
AG05836B-15 stained with MYL7 showing the typical cardiac sarcomere organization; (iii) hESC-H1 co-stained 
for conexin43 in TNNT2 positive cells showing the formation of both organized sarcomeres and gap junctions; 






reduction of the FPA/FPD ratio, also called field potential amplitude upstroke speed (FPUS), an indicator of 
sodium and L-type calcium channel  function27 (Fig. 7Bv, Table 1).
Discussion
The aim of this study was to develop a scaled down platform for cardiac differentiation that was amenable for 
high throughput screening, efficient and reproducible without any genetic modification or additional enrich-
ment processes, while at the same time reducing overall cost. We modified the monolayer-based, small molecule 
approach described by Lian and  colleagues8 to achieve these goals. We replaced 12-well plate with 96-well plate 
format, mTeSR1 medium with the simpler Essential 8 formulation and substituted Matrigel with the cheaper 
and more defined extra cellular matrix, Geltrex at the undifferentiated hPSC expansion stage. This combination 
of modifications reduced the cost of differentiation while still yielding high levels of TNNT2 positive cells at 
later stages of differentiation.
The impact of confluency on differentiation has been  addressed12,18 and we also showed that the yield of 
differentiated cardiomyocytes was highly dependent on hPSC colony density (Fig. 2, Supplementary Fig. S1). 
Thus, the 12-well format produced the best yield at a confluency of 85–90%7,28, whereas in 96-well plates, we 
Figure 5.  Verification of cardiomyocytes differentiation using flow cytometric analysis. (A) Results presented 
as the percentage of TNNT2 and MYL7 positive cells in different hiPSC lines (Detroit 551-A and AG05836B-15) 
and hESC lines (H1 and H9). Detroit 551-A (85%) and H1 (82%) showed higher level of TNNT2 positive cells 
compared to AG05836B-15 (66%) and H9 (47%). Bar graphs showing average and error bars represent ± SD of 
at least three independent differentiation runs (except MLY7 for H9 which is represents a single differentiation 
run). (B) Cardiomyocytes derived from hESC-H1and hiPSC lines (Detroit 551-A and AG05836B-15) were 
collected on Day 15 of differentiation and stained with either surface (CD144-FITC and CD140b-PE) or 
intracellular markers (TNNT2). Cells were stained first to distinguish live/dead cells and then co-stained with 
conjugated antibodies against surface markers including CD144-FITC and CD140b-PE or stained for the 
intracellular marker, TNNT2. The H1-derived cardiomyocyte culture with 74.5%  TNNT2+ cells contained 9.5% 
CD140b positive and 3.7% CD144 positive cells. In the Detroit 551-A culture that 77% of the cells were positive 
for TNNT2, 18% and 5% of the cells were positive for CD140b and CD144 respectively. In addition, while 21% 
of the cell in AG05836B-15 culture expressed smooth muscle marker, only 2% of the cells expressed endothelial 
marker. This culture contained 67% TNNT2 positive cells. (C) Results of immunofluorescent staining showing 
positive staining for either the smooth muscle marker ACTA2 (scale bar, 100 μm) or the endothelial cell marker 
CDH5 (Scale bars, 50 μm). Blue is DAPI and green is Alexa-448 stained ACTA2 (smooth muscle marker) and 





found that a confluency of 60–70% gave excellent numbers of cardiomyocytes (H1 82%, Detroit551-A 85%). 
Further, we observed that CHIR99021 had to be adjusted to altered  confluency10,29 and that the concentration 
was dependent on the cell type used for differentiation. Cardiomyocytes derived from the hESC lines H1 and H9 
required a higher CHIR990201 concentration than those derived from hiPSCs (Detroit 551-A and AG05836B-15) 
to achieve an optimal differentiation yield. The yield of cardiomyocytes did vary between the two hiPSC lines 
(85% for Detroit 551-A and 66% for AG05836B-15). This might be due to the different reprogramming systems 
used (Detroit 551-A—retroviral reprogrammed, AG05836B-15 integration free Sendai virus reprogramed), but 
we did not investigate this in detail.
Moreover, we assessed the expression of key genetic markers in the cultures to validate the developmental 
trajectory towards a cardiomyocyte fate (Fig. 3, Supplementary Fig. S2 and Fig. S3A). ISL-1 is one of the key 
markers for cardiac progenitors and it has been shown that ISL-1 expression levels gradually decline in committed 
cardiomyocytes after its rise at the progenitor stage (day 5)30,31. Of note, H1 followed this pattern and resulted in 
a high level of TNNT2 + (more than 80%), while the expression level of ISL-1 remained high throughout the H9 
differentiation resulting in 47% TNNT2 positive cells (Supplementary Fig. S3A). Our findings, which are similar 
to previous reports showing the poor differentiation capacity of H9 toward cardiomyocytes, may be explained 
by the inability to reduce expression of ISL-1 after the progenitor  stage23. Correct expression patterns of mature 
cardiomyocytes markers such as HOPX, MYH6, MYH7 and NKX2.5 on D30 of differentiation confirmed the 
maturity of the cardiomyocytes generated in this 96-well microplate format (supplementary Fig. S4)6.
Cardiovascular progenitors are able to develop into cardiomyocytes, endothelial cells, cardiac fibroblasts and 
smooth muscle cells. Using our protocol, we demonstrated that between day 10 and 15 the majority of hPSC 
derived cardiomyocytes stained for TNNT2 as well as MYL7 (Fig. 5A). We also investigated the non-cardiomyo-
cyte populations generated using our protocol. The number of TNNT2 positive varied between 64 ± 8% for hESC 
and 76 ± 8% for hiPSC. Differentiation of H1 resulted in 3–4% endothelial cells and 9–11% smooth muscle cells. 
The percentage of endothelial cells in hiPSC-derived cultures was higher than in ES derived cultures with 18.45% 
in Detroit 551-A and 21% in AG05836B-15, smooth muscle cell numbers were lower in the Detroit 551-A and 
AG05836B-15 hiPSC lines compared to H1 (Fig. 5B).
In order to ensure that each well of the 96 well plate provided a similar complement of cells, an important 
factor if we are to use this method for e.g. drug screening, we investigated the well-to-well heterogeneity in our 
cultures. We used both immunocytochemistry and RT-qPCR to determine the relative amount of cardiomyocytes 
in each well. We used microscopy to assess the homogeneity of the cardiomyocyte population and found that 
the cultures contained high numbers of TNNT2 positive cells at day 10 (Fig. 4). We also studied the composi-
tion using PCR to identify the cardiac specific marker TNNT2 and NKX2-5 (Fig. 6). This assay suggested that 
there was a low heterogeneity between the wells of one run of differentiation and between two separate runs of 
Figure 6.  Investigation of inter-well heterogeneity across a 96 well plate and different runs of differentiation. 
The boxplot analysis shows the variation in expression of two cardiomyocyte markers, TNNT2 and NKX2-5 
related to the house keeping gene GAPDH in the ES line H1 and the iPSC line Detroit 551-A. Cells in both 
runs were > 25 days of differentiation. Run 1 comprises 12 separate well samples collected from one plate 
of differentiation of H1 while Run 2 comprises 12 samples taken from 3 different plates of one round of H1 





differentiation. These results demonstrate that this smaller format method produces reproducible cardiomyocyte 
populations both within a single plate and in different runs of differentiation.
Our electrophysiological data (Fig. 7, Table 1) are in line with previous publications and confirm that the 
cardiomyocytes produced by this method are physiologically functional. Beating rate increased in both, car-
diomyocytes derived from H1 and Detroit 551-A following addition of the β-adrenergic agonist isoprenaline, 
known to have a positive chronotropic effect on hPSC-derived  cardiomyocytes32,33. Our cardiomyocytes also 
showed TTX-sensitive and TTX-resistance  Na+ channels: TTX induced a significant reduction of pPA, without 
complete elimination as demonstrated  previously34,35. Furthermore, manipulation of  K+ efflux by E4031, L-type 
VGCC dependent calcium influx by Nifidipine or 5-Hydroxytryptamine (serotonin) receptor—HT4/HT3 func-
tion by Mesopride showed a clear alterations of cardiomyocyte extracellular FP trace that was consistent with 
the previous  reports5. These findings suggest that our established 96-well format in vitro system recapitulates 
the functional characteristics of cardiomyocytes.
Several approaches to enrich the cardiomyocyte population have been described including genetic-modi-
fication (by the expression of MYH6), using surface protein as a specific marker for cardiomyocytes (signal-
regulatory protein alpha) or selection based on targeting highly active mitochondria using a mitochondrial 
membrane potential marker (TMRM)36–38.
Figure 7.  MEA Recording of hiPSC-derived cardiomyocytes. (A) Representative trace recorded with the 
MEA showing the analysis parameter to evaluate the functionality of hiPSC-derived cardiomyocytes. R/Q 
and T peak; field potential duration (FPD), field potential amplitude (FPA), Q/R peak differentiated into 
positive peak amplitude (pPA) and negative peak amplitude (nPA), beat interval (BI); (B) Representative 
the electrophysiological properties of H1-derived cardiomyocytes before (no-drug) and after applying (i) 
β1 and β2 adrenoreceptor agonist Isoproterenol (ISO), (ii) potassium channel antagonist E403, (iii) sodium 
channel antagonist tetrodotoxin (TTX), (iv) L-type calcium channel antagonist Nifedipine (NIF) and (v) 
5-Hydroxytryptamine (serotonin) receptor -HT4 agonist and HT3 antagonist Mosapride (MOS). The shaded 
area represents the field potential duration (FPD), also known as QT interval, measured during analysis. 
Electrophysiological parameters were analyzed and visualized using the analysis tools Analyzer and Spike sorter 





One of the most effective and straightforward approaches appears to be the metabolic selection using lactate 
instead of glucose to force the cells to use their respiratory chain instead of glycolysis and selecting cardiac cells 
based on their energy  profile28,39,40.
Since we are interested in studying disease mechanisms, one key aim of our study was to produce a high 
number of cardiomyocytes without over manipulation, as this may have unwanted cellular and molecular effects. 
We did not therefore investigate the use of these additional measures. Our protocol results in a high percent-
age of cardiomyocytes that express the cardiac marker TNTN2 in both hESCs and hiPSCs without the use of 
any purification method. In principle, however, any of these methods could be combined with our protocol to 
further enhance purification.
Although, well-defined differentiation conditions have greatly improved reproducibility of differentiation, 
inter-experimental reproducibility still remains a key  challenge12. The strength of this protocol is the 96-well 
format, which allows inter-experimental comparability, thus potentially reducing inter-experimental variability 
and increasing the precision of reported results. Further, it offers the possibility of combining differentiated 
cells from different wells or pooling data from individual wells of the 96-well format to balance out the inter-
experimental variation and improve reproducibility. This protocol also demonstrates it is not necessary to first 
differentiate the cells in larger format before reseeding them in to 96 wells for experimentation such as high 
throughput  analysis41,42.
Conclusion
Here we have demonstrated the efficient differentiation of cardiomyocytes in a 96-well microplate format, that 
reduces both workload and cost, improving both consistency and precision. This platform provides an adapt-
able system for monitoring the differentiation and development of cardiac tissue from very early stages all the 
way to functional tissue in 96-well format and is well suited to the investigation of early disease development.
Material and methods
hiPSC generation and characterization. H1 and H9 were obtained from WiCell Research Institute 
(Madison, Wisconsin, WiCell) and well characterized as previously  described1. Detroit 551-A fibroblasts were 
obtained from ATCC (American Type Culture Collection), AG05836B-15 fibroblasts were obtained from the 
Coriell Cell Repositories and reprogramed into hiPSCs and characterized as previously described in Mathipathi 
et al.19,20.
Cardiomyocyte differentiation. Geltrex (#A1413302, Thermo Fisher Scientific) was diluted 1:100 in ice 
cold Advanced DMEM/F-12 (#12634010, Thermo Fisher Scientific) to coat wells in the 96-well plate (85 µl/well). 
Coated plates were incubated at 37 °C for at least 30 min before use. Before plating the hiPSC cells, colonies were 
broken down to single cells after treating with 0.5 mM EDTA to have a homogeneous cell suspension. Human 
iPSCs were seeded in Geltrex coated wells at a density of 2.4 × 104 cells/cm2 using Essential 8 Medium (E8) 
(#A1517001, Thermo Fisher Scientific) supplemented with 10 µM Rock inhibitor (Y27632; #1254, Tocris Biosci-
ence) for 24hrs. After 24hrs, the medium was changed with freshly prepared E8 medium without Y27632 and 
medium was exchanged every day. After two or three days, when the confluency of the culture reached 60–70%, 
Table 1.  Electrophysiological properties of H1- and Detroit551A-derived cardiomyocytes. ISO Isoproterenol, 
TTX Tetrodotoxin, NIF nifedipine, MOS mosaprid, BI beat interval, FPA field potential amplitude, FPD field 
potential amplitude, FPUS field potential amplitude upstroke speed, pPA positive peak amplitude, nC numbers 
of independent cultures, nR numbers of independent recordings, statistic: mean ± SEM, paired-nonparametric 
Wilcoxen signed rank test.
Drugs
CM 
line Exp Groups BI (beats/min) FPA (µV) FPD (ms) FPUS (µV/ms) pPA (µV)
ISO 
1 µM
H1 nC = 6;  nR = 11;









ISO 78 ± 3 70.7 ± 10.2 183 ± 14 0.44 ± 0.07 264.1 ± 30.2
Detroit 
551-A
nC = 3; 
 nR = 4;









ISO 64 ± 7 54.3 ± 5.9 57 ± 8 1.41 ± 0.32 81.0 ± 10.6
E4031 
1 µM
H1 nC = 6;  nR = 10;









E4031 42 ± 1 36.9 ± 4.0 651 ± 47 0.07 ± 0.01 113.4 ± 18.5
Detroit 
551-A
nC = 3; 
 nR = 3;









E4031 66 ± 1 32.4 ± 3.7 143 ± 21 0.28 ± 0.02 143.6 ± 13.8
TTX 
5 µM
H1 nC = 6;  nR = 12;









TTX 25 ± 2 109.4 ± 11.0 394 ± 23 0.35 ± 0.05 147.4 ± 20.4
Detroit 
551-A
nC = 3; 
 nR = 3;









TTX 33 ± 7 67.3 ± 13.2 40 ± 3 1.35 ± 0.32 123.6 ± 13.6
NIF 
5 nM H1
nC = 6; 
 nR = 10;









NIF 36 ± 2 69.9 ± 12.0 195 ± 10 0.36 ± 0.06 111.3 ± 15.9
MOS 
350 nM H1
nC = 6; 
 nR = 11;














cells were treated with 6 µM (optimal concentration for hiPSC) or 8 µM (optimal concentration for hESC) of 
CHIR99021 (#4423, Tocris Bioscience) in RPMI 1640 (#61,870, Thermo Fisher Scientific) supplemented with 
B27-without insulin (#A1895601, Thermo Fisher Scientific). After 24  h the medium containing CHIR99021 
was changed to RPMI-B27 without insulin alone and left for 48 h. On day 3 cells were treated with 5 µM IWP2 
(#3533, Tocris Bioscience) diluted in RPMI-B27 without insulin and incubated for 48 h. On day 5 medium was 
changed to freshly prepared RPMI-B27 without insulin for 48 h. At day 7 medium was changed to RPMI-B27 
with insulin (#17,504,044, Thermo Fisher Scientific) without any extra supplement and medium was changed 
every two days thereafter. Schematic representation of the protocol (Fig. 1A). Working volume in all the steps of 
the protocol was 200 µl per well of 96-well plate.
Gene expression via real‑time PCR. RNA used for gene expression studies was isolated by MagMAX-96 
Total RNA Isolation Kit (#AM1830, Thermo Fisher Scientific). Cells were lysed using lysis buffer supplemented 
by the kit directly inside the plate after a quick wash with PBS. Lysate was either processed immediately for RNA 
isolation using an automated MagMAX express 96 or stored in—80 °C for later extraction. cDNA synthesis and 
Real-time qPCR were performed using EXPRESS One-Step Superscript qRT-PCR Kit (#11781-01 K,Thermo 
Fisher Scientific) and TaqMan probes (see Supplementary Table S2 online). Applied Biosystems 7500-Fast real-
time PCR System (Thermo Fisher Scientific) was used to perform qPCR. All qPCR reactions were performed 
in triplicate and normalized to the geometric mean of ACTB and GAPDH as endogenous control genes, and 
assessed using the comparative ΔΔCt method by normalizing differentiated cells to undifferentiated pluripotent 
stem cells. Results are shown as the mean of three independent differentiation runs and error bars represent 
standard deviation of the mean.
Fluorescent microscopy. Cells of single well of 96 well plate were seeded either on Geltrex coated glass 
coverslips or in Geltrex coated Millicell EZ SLIDES (#PEZGS0816, Merck Millipore). Cells were fixed with 4% 
paraformaldehyde (#43368, Alfa Aesar) for 10 min at room temperature and permeabilized with 0.3% Tween 
20 (#822184, Merck Millipore) diluted in PBS for 1 hr at room temperature. All the primary and secondary 
antibodies were diluted in blocking buffer consisting of 0.3 M glycine, 5% goat serum and 1% BSA in PBS. Final 
concentration of 10 µg/ml was used for all the primary antibodies and incubated overnight at 4 °C. Alexa Fluor 
488 and 568 (Thermo Fisher Scientific) was used as secondary antibodies and were diluted in blocking buffer 
(1:1000) and incubated for 1 h at room temperature. Nuclei were stained with Gold Antifade Reagent with DAPI 
(#P36935, Thermo Fisher Scientific). Confocal microscopy images were taken by either Zeiss LSM 510 META or 
Leica TCS SP5 at Molecular Imaging Center (MIC), University of Bergen, and data analysis and image editing 
were done with  Fiji43. Antibodies are listed in Supplementary Table S2 online.
Flow cytometry. Sample preparation for detecting extracellular antigens; surface markers. Cells were dis-
sociated into single cells using 100 µl TrypLE Express Enzyme (Thermo Fisher Scientific) for 20 min at 37 °C 
and after a quick wash with PBS. Cells were collected after adding 100 µl of culture medium (e.g. RPMI B27 +) 
supplemented with 20% FBS and each eight wells of 96-well format were pooled and filtered using 40 μm pre-wet 
cell strainer (# 431750, Sigma). Each sample counted prior to spinning down at 400 g for 5 min at RT.
Cell pellet was resuspended in Running buffer consisting of autoMACS Rinsing Solution (#130-091-222, 
Miltenyi Biotec) and MACS BSA Stock Solution (# 130-091-376, Miltenyi Biotec)-final concentration of BSA 
was 0.5%. Number of cells in each sample was adjusted for  105 cells/100 μl. Cells were stained with Dead cell 
Discriminator (1:50), provided by the Fixation and Dead Cell Discrimination Kit (#130-091-163, Miltenyi Bio-
tec) and incubated on ice while exposing to a 60 W light bulb for 10 min. Subsequently, the optimal concentra-
tion of conjugated antibodies for flow cytometry reported by the supplier for each batch was used. Cells were 
incubated for 10 min at 4 °C in the dark with pre-conjugated antibodies; CD144- FITC and CD140b-PE. Cells 
were washed by adding 1 ml of running buffer per  105 cells and spinning down at 300 g for 10 min at RT. Cell 
pellet was resuspended in 300 μl of running buffer and cells were fixed by adding 150 μl of FiX solution and 
5 μl of Discriminator Stop Reagent provided by the Fixation and Dead Cell Discrimination Kit. Fluorescence 
minus one control was used to adjust the gate for positive cells, due to the co-staining for live/dead staining and 
different markers within one sample. Proper Isotype controls and compensation beads were also included for 
gating (Supplementary Fig. S5). At least 30,000 events were collected for each sample with a 100 µm nozzle by a 
Sony cell sorter SH800 (Sony Biotechnology Inc.) and data were analyzed and visualized using FlowJo V.10.5.0 
(FlowJo LLC, OR, USA) software (www.FlowJ o.com). Antibodies are listed in Supplementary Table S2 online.
Sample preparation for detecting the intracellular antigens. Cells were washed in DPBS (#14190250, Ther-
moFisher) three times and dissociated into single cells using Enzyme T diluted in Buffer X (1:10) provided by 
Multi Tissue Dissociation Kit 3 (#130-110-204, Miltenyi Biotec) for 10–15 min at 37 °C. Equal volume of culture 
medium (e.g. RPMI B27 +) supplemented with 20% FBS was added to each well and each eight wells of 96-well 
format were pooled and filtered using 40 μm pre-wet cell strainer (# 431750, Sigma). Cells were counted prior 
to spinning down at 400 g for 5 min at RT. Cell pellet was resuspended in InsideFix solution, provided by Inside 
Stain Kit (#130-090-477, Miltenyi Biotec), diluted in DPBS (1:1) and incubated for 10 min at RT. Number of 
cells in each sample was adjusted for  105 cells/100 μl. Cells were washed by adding 1 ml of running buffer per 
 105 cells and spinning down at 300 g for 10 min at RT. Cell pellet was resuspended in Inside Perm solution—a 
component of the Inside Stain Kit- and stained with recommended dilution of pre-conjugated antibodies for 
10 min in the dark at RT. Antibodies were pre-conjugated with Fluorescein isothiocyanate (FITC). Cells were 
washed with 1 ml Inside Perm solution per  105 cells for 5 min at 400 g. Cell pellet was resuspended in 300 μl of 





cells (Supplementary Fig. S5). At least 30,000 events were collected for each sample with a 100 µm nozzle by a 
Sony cell sorter SH800 (Sony Biotechnology Inc.) and data were analyzed and presented using V.10.5.0 (FlowJo 
LLC, OR, USA, www.FlowJ o.com) software. Antibodies are listed in Supplementary Table S2 online.
NOTE: Adherent cardiomyocytes generated in 96 well plate were dissociated into single cells by using TrypLE 
Express enzyme for detecting extracellular antigens and using Multi Tissue Dissociation Kit 3 for detecting intra-
cellular antigen by flow cytometry. The difference between the efficiency of these two methods was not significant 
(P value = 0.17) for dissociating cardiomyocytes. Dissociation of cardiomyocytes in to single cell with Multi Tis-
sue Dissociation Kit 3 was faster specifically for dissociating more mature culture, however it caused changes in 
extracellular antigens structure that could not be detected by antibodies and subsequently, no detectable signal 
for flow cytometric analysis. Therefore, we used TrypLE Express enzyme for detection of extracellular antigens.
Microelectrode array measurements. Human Pluripotent stem cells including H1 and Detroit 551-A 
were differentiated towards the cardiomyocytes as describe in cardiomyocyte differentiation section. At day 
11–14 of differentiation, 1 × 106 cells of cardiomyocyte culture from eight wells of a 96-well plate were pooled, 
and transferred into a single chamber microelectrode array (MEA) unit containing 60 integrated TiN electrodes 
(#60MEA200/30iR-Ti-gr; Multichannel Systems).
To dissociate the cardiomyocytes into single cells or small cell clump of 10–12 cells, cells were quickly washed 
with DPBS and incubated with TRYPLE Express Enzyme (Thermo Fisher Scientific) at 37 °C for 10–15 min 
(100 μl per well). TRYPLE Express Enzyme was neutralized with the equal volume of RPMI-B27 with insulin 
(#17504044, Thermo Fisher Scientific) supplemented with 20% FBS. Collected cells from each well were trans-
ferred into a falcon tube and washed with RPMI-B27 containing insulin and 20% FBS. Cells suspension was 
centrifuged at 400 g for 5 min at RT and cell pellet was gently resuspended in 1 ml of RPMI-B27 with insulin 
supplemented with 10 μM of Y27632 (#1254, Tocris Bioscience) and plated in MEA chamber that was pre-coated 
with Geltrex, 1:100 diluted in Advanced DMEM/F-12, for at least 30 min at 37 °C. After 12 h of incubation at 
37 °C with 5%  CO2, Cardiomyocytes were anchored over the electrode field using a 0.8 g glass coated steel ring 
covered with a nylon mesh (#ALA HSG-MEA-5BD; Multichannel systems). After observing spontaneous beating 
of the cell accumulate 48 h post transferring, field potential (FP) recordings were commenced. At a sampling 
rate of 20 kHz local field potentials at each electrode were collected over a period of 15 min at 35 °C using 
the MEA2100-HS2 × 60 system and the MC-Rack software (Version 4.6.2; Multichannel system, Reutlingen, 
Germany).
FPs were recorded for 5 min under control conditions, after applying chemical compounds such as selective 
β-adrenergic agonist Isoprenternol (ISO, 1 µM; #1747; Tocris),  KV11.1 (hERG) channel antagonist E4031(1 µM; 
#1808; Tocris), L-type  CaV channel antagonist Nifedipine (NIF, 5 nM; #N-120; Alomone), Na channel antagonist 
Tetrodotoxin (TTX, 5 µM; #1069; Tocris) and 5-HT3/4 receptor antagonist Mosapride (MOS, 350 nM; #M-225; 
Alomone) and post-washout.
Electrophysiological parameter analysis. Using the analysis tools Analyzer and Spike sorter in the 
MC_Rack software (Version 4.6.2) positive (pPA) and negative peak amplitude (nPA), field potential duration 
(FPD) and amplitude (FPA) as well as beat interval (BI) were evaluated (Fig. 7A). Field potential amplitude 
upstroke speed was calculated by dividing FPA by FPD. All data sets are represented as mean ± SD compiling 5 
randomly chosen electrodes of at least 5 independent experiments. The chemical compound data were normal-
ized to control for each experiment.
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